Ischemic heart disease is a leading cause of morbidity and mortality in the United States and other parts of the world. Despite the advent of therapeutic breakthroughs over the past decades such as percutaneous coronary intervention, anti-platelet, anti-thrombotic therapies and angioplasty, the prevalence of ischemic heart diseases remains extremely high and constitutes a devastating factor for heart failure 1, 2 . Among various therapeutic strategies for ischemic heart disease, enormous efforts have been made to limit ischemia-reperfusion (I/R) injury that occurs when the ischemic myocardium is reperfused with oxygen and substrate-rich blood which paradoxically worsens heart function 2 . Ischemic myocardium, with nutrient and oxygen deprivation as well as build-up of reactive oxygen species (ROS), uses glycolysis as the primary source for metabolic energy. As a consequence, metabolic acidosis, hyperkalemia and Ca 2+overload develop in cardiomyocytes following coronary artery occlusion, leading not only to cardiomyocyte apoptosis during the acute phase, but also delayed adverse myocardial remodeling that further compromises cardiac function 2 . Therefore, limiting I/R-induced myocardial ROS accumulation and apoptosis benefits both acute and long term survival and quality of life. Although the mechanism(s) responsible for I/R-induced cardiac abnormalities has been focused largely on necrosis and type I (apoptotic) programmed cell death 2 , an intriguing and provocative paradigm has emerged recently highlighting a unique role for dysregulated macroautophagy (hereafter referred to as autophagy) in the heart that may render cardiomyocytes more prone to I/R injury and the long-term post-infarction cardiac remodeling 1, 3 . It has been perceived that autophagy induced by ischemic preconditioning is essential for cardioprotection.
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The Janus Faced Role of Autophagy Induction in I/R Injury
Autophagy is a tightly regulated lysosomal-dependent catabolic process responsible for turnover of long-lived proteins and intracellular structures that are damaged or malfunctioning 4, 5 . The evolutionally conserved bulk degradation process is turned on when cells experiences stress, findings have great clinical relevance as the plasma SAHA levels were similar to those achieved in cancer patients 10 . This work has unveiled a new paradigm for the clinical utility of HDAC inhibitors and autophagy regulators in ischemic heart diseases. A plethora of studies have demonstrated proven cardioprotective benefits of HDAC inhibitors in models of myocardial stress, including cardiac hypertrophy, I/R and heart failure [11] [12] [13] . In particular, trichostatin A (TSA), a class I and II HDAC inhibitor structurally homologous to SAHA, reduces myocardial infarct size up to 50% 14 . HDAC inhibition caused a dramatic increase in phosphorylation of p38 and p38 activity in the heart 14 . Of note, HDAC inhibitors may be delivered as late as one hour following an ischemic insult and achieve a similar degree of infarct size reduction using pretreatment, indicating the suitability of HDAC inhibitors to treat MI at the time of percutaneous coronary intervention. Although discrepancies exist in disease mechanisms in animal models relative to the human case, these data clearly show that facilitated autophagy is required for HDAC inhibition-induced protection against I/R injury 10 . Given the recent therapeutic promises using HDAC inhibitors in ischemic and hypertrophic heart diseases 11, 12, 15, 16 , the finding that SAHA rescues I/R heart injury through modulating autophagy flux is of great clinical importance. Interestingly, a number of cardioprotective agents such as the angiotensin II receptor blocker valsartan may also elicit protection against I/R injury through autophagy induction. Valsartan preconditioning is believed to facilitate autophagy induction via an Akt/mTOR/S6K-mediated mechanism although the underlying molecular mechanism behind SAHA-induced autophagy flux remains unclear at this time.
The New Horizon of HDAC Inhibitors in Heart Diseases
Histone acetylation participates in the regulation of transcription by promoting a more relaxed chromatin structure necessary for transcriptional activation. 11, 11, 12, , 15, reversible acetylation of -amino groups on lysine residues. Reversible protein acetylation is controlled by enzymes that either attach (histone acetyltransferases, HATs) or remove (HDACs) acetyl groups 13 . With the removal of acetyl groups from a -N-acetyl lysine amino acid on a histone to restore the positive charge to lysine residues, HDAC proteins may also be referred to as lysine deacetylases to more precisely recapitulate their function rather than their targets [16] [17] [18] .
Small molecule HDAC inhibitors, acting specifically or broadly on one or more of the four HDACs and on non-histone targets, are currently being tested for oncological indications 16, 18 . 13, 20 . Hill and colleagues recently reported that the prototypical HDAC inhibitor TSA attenuated both load-and agonist-induced hypertrophic myocardial growth through inhibition of autophagy 15 , rather than facilitated autophagy as reported for SAHA 10 . While these findings appear to be contradictory, it is imperative that the HDAC inhibitors strive to restore autophagy homeostasis cardiac remodeling, apoptosis, necrosis, metabolism, contractility and fibrosis 11 Considering the current controversy with regards to the role of adaptive or maladaptive autophagy in cardiac pathology 5 , it is pertinent to better understand conditions in which autophagy should be inhibited or activated to best preserve not only cardiac homeostasis but also optimize drug therapy (such as the drug efficacy and resistance for HDAC inhibitors). 
Gene deletion and overexpression studies have unveiled important functions of HDACs

